Agilon Health Investors Urged to Seek Lead Role in Securities Suit Before March 2 Deadline

Overview

• The federal lawsuit in the Eastern District of New York covers purchases of agilon securities from February 26, 2025 through August 4, 2025.
• Complaints assert that executives issued unachievable 2025 guidance and overstated the immediate benefits of supposed risk‑reduction actions.
• On August 4, 2025, agilon disclosed more acute industry headwinds and suspended its full‑year 2025 financial guidance.
• Shares fell about 51.5% on August 5, 2025 following the company’s disclosure of the guidance suspension.
• Bernstein Liebhard, Levi & Korsinsky, Faruqi & Faruqi, and the Law Offices of Howard G. Smith are inviting investors to move for lead‑plaintiff status by March 2, 2026, with firms noting that investors can still share in any recovery without serving.